Download PDF
Thorac Cardiovasc Surg 2013; 61(04): 307-311
DOI: 10.1055/s-0033-1337446
Original Cardiovascular
Georg Thieme Verlag KG Stuttgart · New York

Cyclooxygenase-2 Expression in Lung in Patients with Congenital Heart Malformations and Pulmonary Arterial Hypertension

Tsvetomir Loukanov
1   Department of Cardiac Surgery, University of Heidelberg, Heidelberg, Germany
,
Christoph Jaschinski
1   Department of Cardiac Surgery, University of Heidelberg, Heidelberg, Germany
,
Milen Kirilov
2   Department of Molecular Metabolic Control, German Cancer Research Center, Heidelberg, Germany
,
Homa Klimpel
3   Department of Pediatric Cardiology, University of Heidelberg, Heidelberg, Germany
,
Matthias Karck
1   Department of Cardiac Surgery, University of Heidelberg, Heidelberg, Germany
,
Matthias Gorenflo
3   Department of Pediatric Cardiology, University of Heidelberg, Heidelberg, Germany
› Author Affiliations
Further Information

Publication History

26 July 2012

21 December 2012

Publication Date:
16 May 2013 (online)

    Permissions and Reprints All articles of this category

Abstract

Background Pulmonary arterial hypertension (PAH) is a cause of morbidity in patients with congenital heart disease (CHD). It has been hypothesized that prostanoides participate in the development of PAH. The aim of this study was to show the potential expression of cyclooxygenase-2 (COX-2) in patients with CHD and PAH.

Patients and Methods We included patients with isolated left-to-right shunts undergoing lung biopsy before or concomitantly with cardiac surgery between 2004 and 2009.

For determination of COX-2 expression, histological and immunohistochemistry analyses as well as quantitative polymerase chain reaction (qPCR) were performed.

Results We were able to show COX-2 protein overexpression in the lung tissue of children with CHD and PAH. Furthermore, we showed an increase in COX-1 gene expression and an even stronger induction of COX-2 by using qPCR and immunohistochemistry.

Conclusions We examined the expression of COX-2 in lung tissue from patients with CHD and PAH. We showed that COX-2 is expressed in diseased lung tissue, indicating a relationship between COX-2 and vascular remodeling in pulmonary arteries in CHD.

Keywords

congenital heart disease - pulmonary vascular resistance/hypertension - surgery - complications
 

  • References

  • 1 Lindberg L, Olsson AK, Jögi P, Jonmarker C. How common is severe pulmonary hypertension after pediatric cardiac surgery?. J Thorac Cardiovasc Surg 2002; 123 (6) 1155-1163
    CrossrefPubMedGoogle Scholar
  • 2 Humbert M, Morrell NW, Archer SL , et al. Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol 2004; 43 (12, Suppl S): 13S-24S
    CrossrefPubMedGoogle Scholar
  • 3 Bando K, Turrentine MW, Sharp TG , et al. Pulmonary hypertension after operations for congenital heart disease: analysis of risk factors and management. J Thorac Cardiovasc Surg 1996; 112 (6) 1600-1607 , discussion 1607–1609
    CrossrefPubMedGoogle Scholar
  • 4 Tuder RM, Cool CD, Geraci MW , et al. Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension. Am J Respir Crit Care Med 1999; 159 (6) 1925-1932
    CrossrefPubMedGoogle Scholar
  • 5 Christman BW, McPherson CD, Newman JH , et al. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N Engl J Med 1992; 327 (2) 70-75
    CrossrefPubMedGoogle Scholar
  • 6 Geraci MW, Gao B, Shepherd DC , et al. Pulmonary prostacyclin synthase overexpression in transgenic mice protects against development of hypoxic pulmonary hypertension. J Clin Invest 1999; 103 (11) 1509-1515
    CrossrefPubMedGoogle Scholar
  • 7 Rubin LJ, Mendoza J, Hood M , et al. Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). Results of a randomized trial. Ann Intern Med 1990; 112 (7) 485-491
    CrossrefPubMedGoogle Scholar
  • 8 Hoshikawa Y, Voelkel NF, Gesell TL , et al. Prostacyclin receptor-dependent modulation of pulmonary vascular remodeling. Am J Respir Crit Care Med 2001; 164 (2) 314-318
    CrossrefPubMedGoogle Scholar
  • 9 Fredenburgh L, Liang O, Macias A , et al. Absence of cyclooxygenase-2 exacerbates hypoxia-induced pulmonary hypertension and enhances contractility of vascular smooth muscle cells. Circulation 2008; 117: 2114-2122
    CrossrefPubMedGoogle Scholar
  • 10 Loukanov T, Geiger R, Agrawal R. Animal models related to congenital heart disease and clinical research in pulmonary hypertension. Cardiology 2010; 116 (1) 18-25
    CrossrefPubMedGoogle Scholar
  • 11 Delannoy E, Courtois A, Freund-Michel V, Leblais V, Marthan R, Muller B. Hypoxia-induced hyperreactivity of pulmonary arteries: role of cyclooxygenase-2, isoprostanes, and thromboxane receptors. Cardiovasc Res 2010; 85 (3) 582-592
    CrossrefPubMedGoogle Scholar
  • 12 Carratelli M, Porcaro L, Ruscica M, De Simone E, Bertelli AA, Corsi MM. Reactive oxygen metabolites and prooxidant status in children with Down's syndrome. Int J Clin Pharmacol Res 2001; 21 (2) 79-84
    PubMedGoogle Scholar
  • 13 Fike CD, Slaughter JC, Kaplowitz MR, Zhang Y, Aschner JL. Reactive oxygen species from NADPH oxidase contribute to altered pulmonary vascular responses in piglets with chronic hypoxia-induced pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol 2008; 295 (5) L881-L888
    CrossrefPubMedGoogle Scholar
  • 14 Farrow KN, Lakshminrusimha S, Reda WJ , et al. Superoxide dismutase restores eNOS expression and function in resistance pulmonary arteries from neonatal lambs with persistent pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol 2008; 295 (6) L979-L987
    CrossrefPubMedGoogle Scholar
  • 15 Lakshminrusimha S, Wiseman D, Black SM , et al. The role of nitric oxide synthase-derived reactive oxygen species in the altered relaxation of pulmonary arteries from lambs with increased pulmonary blood flow. Am J Physiol Heart Circ Physiol 2007; 293 (3) H1491-H1497
    CrossrefPubMedGoogle Scholar